Abstract
Drug-resistant epilepsy (DRE), also known as intractable epilepsy or refractory epilepsy, is a disease state with long-term poorly controlled seizures attack. Without effective treatment, patients are at an elevated risk of injury, premature death, mental disorders, and poor quality of life, increasing the need for a fresh perspective on the etiology and treatment of DRE. The gut is known to harbor a wide variety of microorganisms that can regulate the host’s response to exogenous signals and participate in various physiological and pathological processes in the human body. Interestingly, emerging evidence has uncovered the changes in gut microbiota in patients with epilepsy, particularly those with DRE. In addition, both dietary interventions and specific antibiotic therapy have been proven to be effective in restoring the microecological environment and, more importantly, reducing seizures. Here, we reviewed recent studies on DRE and the involvement of gut microbiota in it, describing changes in the gut microflora composition in patients with DRE and corresponding animal models. Furthermore, the influence of the ketogenic diet, probiotics, fecal microbiota transplantation (FMT), and antibiotics as microbiome-related factors on seizure control and its possible mechanisms are broadly discussed. Finally, we highlighted the significance of gut microbiome in DRE, in order to provide a new prospect for early identification and individualized treatment of patients with DRE.
Similar content being viewed by others
Data Availability
Not applicable.
References
Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, Engel J Jr (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46(4):470–472. https://doi.org/10.1111/j.0013-9580.2005.66104.x
Thijs RD, Surges R, O'Brien TJ, Sander JW (2019) Epilepsy in adults. Lancet (London, England) 393(10172):689–701. https://doi.org/10.1016/S0140-6736(18)32596-0
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6):1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x
Hakami T (2021) Efficacy and tolerability of antiseizure drugs. Ther Adv Neurol Disord 14:17562864211037430. https://doi.org/10.1177/17562864211037430
Löscher W, Potschka H, Sisodiya SM, Vezzani A (2020) Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev 72(3):606–638. https://doi.org/10.1124/pr.120.019539
Perucca P, Gilliam FG (2012) Adverse effects of antiepileptic drugs. Lancet Neurol 11(9):792–802. https://doi.org/10.1016/S1474-4422(12)70153-9
Zhang X, Li L, Butcher J, Stintzi A, Figeys D (2019) Advancing functional and translational microbiome research using meta-omics approaches. Microbiome 7(1):154. https://doi.org/10.1186/s40168-019-0767-6
Franzosa EA, Hsu T, Sirota-Madi A, Shafquat A, Abu-Ali G, Morgan XC, Huttenhower C (2015) Sequencing and beyond: integrating molecular ‘omics’ for microbial community profiling. Nat Rev Microbiol 13(6):360–372. https://doi.org/10.1038/nrmicro3451
Heinken A, Basile A, Hertel J, Thinnes C, Thiele I (2021) Genome-scale metabolic modeling of the human microbiome in the era of personalized medicine. Annu Rev Microbiol 75:199–222. https://doi.org/10.1146/annurev-micro-060221-012134
Cryan JF, O'Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S et al (2019) The microbiota-gut-brain axis. Physiol Rev 99(4):1877–2013. https://doi.org/10.1152/physrev.00018.2018
Wang H-X, Wang Y-P (2016) Gut microbiota-brain axis. Chin Med J (Engl) 129(19):2373–2380. https://doi.org/10.4103/0366-6999.190667
Chen Y, Xu J, Chen Y (2021) Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients 13(6). https://doi.org/10.3390/nu13062099
Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG (2020) The gut microbiome in neurological disorders. Lancet Neurol 19(2):179–194. https://doi.org/10.1016/S1474-4422(19)30356-4
Socała K, Doboszewska U, Szopa A, Serefko A, Włodarczyk M, Zielińska A, Poleszak E, Fichna J et al (2021) The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res 172:105840. https://doi.org/10.1016/j.phrs.2021.105840
Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY (2018) The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173(7):1728–1741.e1713. https://doi.org/10.1016/j.cell.2018.04.027
Dahlin M, Prast-Nielsen S (2019) The gut microbiome and epilepsy. EBioMedicine 44:741–746. https://doi.org/10.1016/j.ebiom.2019.05.024
Holmes M, Flaminio Z, Vardhan M, Xu F, Li X, Devinsky O, Saxena D (2020) Cross talk between drug-resistant epilepsy and the gut microbiome. Epilepsia 61(12):2619–2628. https://doi.org/10.1111/epi.16744
Ding M, Lang Y, Shu H, Shao J, Cui L (2021) Microbiota-gut-brain axis and epilepsy: a review on mechanisms and potential therapeutics. Front Immunol 12:742449. https://doi.org/10.3389/fimmu.2021.742449
Chatzikonstantinou S, Gioula G, Kimiskidis VK, McKenna J, Mavroudis I, Kazis D (2021) The gut microbiome in drug-resistant epilepsy. Epilepsia Open 6(1):28–37. https://doi.org/10.1002/epi4.12461
Yue Q, Cai M, Xiao B, Zhan Q, Zeng C (2022) The microbiota-gut-brain axis and epilepsy. Cell Mol Neurobiol 42(2):439–453. https://doi.org/10.1007/s10571-021-01130-2
Sorboni SG, Moghaddam HS, Jafarzadeh-Esfehani R, Soleimanpour S (2022) A comprehensive review on the role of the gut microbiome in human neurological disorders. Clin Microbiol Rev 35(1):e0033820. https://doi.org/10.1128/CMR.00338-20
Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V (2018) The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia 59(12):2179–2193. https://doi.org/10.1111/epi.14596
Gavvala JR, Schuele SU (2016) New-onset seizure in adults and adolescents: a review. Jama 316(24):2657–2668. https://doi.org/10.1001/jama.2016.18625
Kostic D, Carlson R, Henke D, Rohn K, Tipold A (2019) Evaluation of IL-1β levels in epilepsy and traumatic brain injury in dogs. BMC Neurosci 20(1):29. https://doi.org/10.1186/s12868-019-0509-5
Poyuran R, Mahadevan A, Mhatre R, Arimappamagan A, Sinha S, Bharath RD, Rao MB, Saini J et al (2021) Neuropathological spectrum of drug resistant epilepsy: 15-years-experience from a tertiary care centre. J Clin Neurosci 91:226–236. https://doi.org/10.1016/j.jocn.2021.07.014
Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, Heinemann U, Beck H (2003) A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 53(4):469–479
Schaub C, Uebachs M, Beck H (2007) Diminished response of CA1 neurons to antiepileptic drugs in chronic epilepsy. Epilepsia 48(7):1339–1350
Xu C, Wang Y, Zhang S, Nao J, Liu Y, Wang Y, Ding F, Zhong K et al (2019) Subicular pyramidal neurons gate drug resistance in temporal lobe epilepsy. Ann Neurol 86(4):626–640. https://doi.org/10.1002/ana.25554
Geis C, Planagumà J, Carreño M, Graus F, Dalmau J (2019) Autoimmune seizures and epilepsy. J Clin Invest 129(3):926–940. https://doi.org/10.1172/JCI125178
Husari KS, Dubey D (2019) Autoimmune epilepsy. Neurotherapeutics 16(3):685–702. https://doi.org/10.1007/s13311-019-00750-3
Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M et al (2019) Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia 60(2):303–314. https://doi.org/10.1111/epi.14629
Tang F, Hartz AMS, Bauer B (2017) Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol 8:301. https://doi.org/10.3389/fneur.2017.00301
Salar S, Maslarova A, Lippmann K, Nichtweiss J, Weissberg I, Sheintuch L, Kunz WS, Shorer Z et al (2014) Blood-brain barrier dysfunction can contribute to pharmacoresistance of seizures. Epilepsia 55(8):1255–1263. https://doi.org/10.1111/epi.12713
Vezzani A, Balosso S, Ravizza T (2019) Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol 15(8):459–472. https://doi.org/10.1038/s41582-019-0217-x
Löscher W (2011) Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 20(5):359–368. https://doi.org/10.1016/j.seizure.2011.01.003
Zhang C, Kwan P, Zuo Z, Baum L (2012) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 64(10):930–942. https://doi.org/10.1016/j.addr.2011.12.003
Liu JYW, Thom M, Catarino CB, Martinian L, Figarella-Branger D, Bartolomei F, Koepp M, Sisodiya SM (2012) Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 135(Pt 10):3115–3133. https://doi.org/10.1093/brain/aws147
Brukner AM, Billington S, Benifla M, Nguyen TB, Han H, Bennett O, Gilboa T, Blatch D et al (2021) Abundance of -glycoprotein and breast cancer resistance protein measured by targeted proteomics in human epileptogenic brain tissue. Mol Pharm 18(6):2263–2273. https://doi.org/10.1021/acs.molpharmaceut.1c00083
Ko A, Youn SE, Kim SH, Lee JS, Kim S, Choi JR, Kim HD, Lee S-T et al (2018) Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy. Epilepsy Res 141:48–55. https://doi.org/10.1016/j.eplepsyres.2018.02.003
Calderon-Ospina CA, Galvez JM, López-Cabra C, Morales N, Restrepo CM, Rodríguez J, Aristizábal-Gutiérrez FA et al (2020) Possible genetic determinants of response to phenytoin in a group of Colombian patients with epilepsy. Front Pharmacol 11:555. https://doi.org/10.3389/fphar.2020.00555
Orlandi A, Paolino MC, Striano P, Parisi P (2018) Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy. Expert Opin Drug Metab Toxicol 14(5):505–512. https://doi.org/10.1080/17425255.2018.1473377
Löscher W (2017) Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res 42(7):1873–1888. https://doi.org/10.1007/s11064-017-2222-z
Zubiaur P, Del Peso-Casado M, Ochoa D, Enrique-Benedito T, Mejía-Abril G, Navares M, Villapalos-García G, Román M et al (2021) ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics. Biomed Pharmacother 142:112083. https://doi.org/10.1016/j.biopha.2021.112083
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC (2019) What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7(1). https://doi.org/10.3390/microorganisms7010014
Kennedy KM, Gerlach MJ, Adam T, Heimesaat MM, Rossi L, Surette MG, Sloboda DM, Braun T (2021) Fetal meconium does not have a detectable microbiota before birth. Nat Microbiol. https://doi.org/10.1038/s41564-021-00904-0
Mishra A, Lai GC, Yao LJ, Aung TT, Shental N, Rotter-Maskowitz A, Shepherdson E, Singh GSN et al (2021) Microbial exposure during early human development primes fetal immune cells. Cell. https://doi.org/10.1016/j.cell.2021.04.039
Roswall J, Olsson LM, Kovatcheva-Datchary P, Nilsson S, Tremaroli V, Simon M-C, Kiilerich P, Akrami R et al (2021) Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. Cell Host Microbe 29(5). https://doi.org/10.1016/j.chom.2021.02.021
Peng A, Qiu X, Lai W, Li W, Zhang L, Zhu X, He S, Duan J et al (2018) Altered composition of the gut microbiome in patients with drug-resistant epilepsy. Epilepsy Res 147:102–107. https://doi.org/10.1016/j.eplepsyres.2018.09.013
Gong X, Liu X, Chen C, Lin J, Li A, Guo K, An D, Zhou D et al (2020) Alteration of gut microbiota in patients with epilepsy and the potential index as a biomarker. Front Microbiol 11:517797. https://doi.org/10.3389/fmicb.2020.517797
Lee H, Lee S, Lee DH, Kim DW (2021) A comparison of the gut microbiota among adult patients with drug-responsive and drug-resistant epilepsy: an exploratory study. Epilepsy Res 172:106601. https://doi.org/10.1016/j.eplepsyres.2021.106601
Xie G, Zhou Q, Qiu CZ, Dai WK, Wang HP, Li YH, Liao JX, Lu XG et al (2017) Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy. World J Gastroenterol 23(33):6164–6171. https://doi.org/10.3748/wjg.v23.i33.6164
Zhang Y, Zhou S, Zhou Y, Yu L, Zhang L, Wang Y (2018) Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet. Epilepsy Res 145:163–168. https://doi.org/10.1016/j.eplepsyres.2018.06.015
Gong X, Cai Q, Liu X, An D, Zhou D, Luo R, Peng R, Hong Z (2021) Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets. Microb Pathog 155:104899. https://doi.org/10.1016/j.micpath.2021.104899
Lindefeldt M, Eng A, Darban H, Bjerkner A, Zetterström CK, Allander T, Andersson B, Borenstein E et al (2019) The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy. NPJ biofilms and microbiomes 5(1):5. https://doi.org/10.1038/s41522-018-0073-2
Żarnowska I, Wróbel-Dudzińska D, Tulidowicz-Bielak M, Kocki T, Mitosek-Szewczyk K, Gasior M, Turski WA (2019) Changes in tryptophan and kynurenine pathway metabolites in the blood of children treated with ketogenic diet for refractory epilepsy. Seizure 69:265–272. https://doi.org/10.1016/j.seizure.2019.05.006
Gómez-Eguílaz M, Ramón-Trapero JL, Pérez-Martínez L, Blanco JR (2018) The beneficial effect of probiotics as a supplementary treatment in drug-resistant epilepsy: a pilot study. Beneficial microbes 9(6):875–881. https://doi.org/10.3920/bm2018.0018
Cheraghmakani H, Rezai MS, Valadan R, Rahimzadeh G, Moradi M, Jahanfekr V, Moosazadeh M, Tabrizi N (2021) Ciprofloxacin for treatment of drug-resistant epilepsy. Epilepsy Res 176:106742. https://doi.org/10.1016/j.eplepsyres.2021.106742
He Z, Cui B-T, Zhang T, Li P, Long C-Y, Ji G-Z, Zhang F-M (2017) Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: the first report. World J Gastroenterol 23(19):3565–3568. https://doi.org/10.3748/wjg.v23.i19.3565
Nowak M, Strzelczyk A, Reif PS, Schorlemmer K, Bauer S, Norwood BA, Oertel WH, Rosenow F et al (2012) Minocycline as potent anticonvulsant in a patient with astrocytoma and drug resistant epilepsy. Seizure 21(3):227–228. https://doi.org/10.1016/j.seizure.2011.12.009
Braakman HMH, van Ingen J (2018) Can epilepsy be treated by antibiotics? J Neurol 265(8):1934–1936. https://doi.org/10.1007/s00415-018-8943-3
Fenoglio-Simeone KA, Wilke JC, Milligan HL, Allen CN, Rho JM, Maganti RK (2009) Ketogenic diet treatment abolishes seizure periodicity and improves diurnal rhythmicity in epileptic Kcna1-null mice. Epilepsia 50(9):2027–2034. https://doi.org/10.1111/j.1528-1167.2009.02163.x
Medel-Matus J-S, Shin D, Dorfman E, Sankar R, Mazarati A (2018) Facilitation of kindling epileptogenesis by chronic stress may be mediated by intestinal microbiome. Epilepsia open 3(2):290–294. https://doi.org/10.1002/epi4.12114
Bagheri S, Heydari A, Alinaghipour A, Salami M (2019) Effect of probiotic supplementation on seizure activity and cognitive performance in PTZ-induced chemical kindling. Epilepsy Behav: E&B 95:43–50. https://doi.org/10.1016/j.yebeh.2019.03.038
Tahmasebi S, Oryan S, Mohajerani HR, Akbari N, Palizvan MR (2020) Probiotics and Nigella sativa extract supplementation improved behavioral and electrophysiological effects of PTZ-induced chemical kindling in rats. Epilepsy Behav E&B 104(Pt A):106897. https://doi.org/10.1016/j.yebeh.2019.106897
Citraro R, Lembo F, De Caro C, Tallarico M, Coretti L, Iannone LF, Leo A, Palumbo D et al (2021) First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. Epilepsia 62(2):529–541. https://doi.org/10.1111/epi.16813
De Caro C, Leo A, Nesci V, Ghelardini C, di Cesare ML, Striano P, Avagliano C, Calignano A et al (2019) Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. Sci Rep 9(1):13983. https://doi.org/10.1038/s41598-019-50542-0
Muñana KR, Jacob ME, Callahan BJ (2020) Evaluation of fecal Lactobacillus populations in dogs with idiopathic epilepsy: a pilot study. Animal Microbiome 2(1). https://doi.org/10.1186/s42523-020-00036-6
Miljanovic N, Potschka H (2021) The impact of Scn1a deficiency and ketogenic diet on the intestinal microbiome: a study in a genetic Dravet mouse model. Epilepsy Res 178:106826. https://doi.org/10.1016/j.eplepsyres.2021.106826
Şafak B, Altunan B, Topçu B, Eren Topkaya A (2020) The gut microbiome in epilepsy. Microb Pathog 139:103853. https://doi.org/10.1016/j.micpath.2019.103853
Vizuete AFK, Hennemann MM, Gonçalves CA, de Oliveira DL (2017) Phase-dependent astroglial alterations in Li-pilocarpine-induced status epilepticus in young rats. Neurochem Res 42(10):2730–2742. https://doi.org/10.1007/s11064-017-2276-y
Lévesque M, Avoli M (2013) The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev 37(10 Pt 2):2887–2899. https://doi.org/10.1016/j.neubiorev.2013.10.011
Huang Y, Wang L, Ren S, Wu G, Wu J (2020) The expression of ZnT3 and GFAP is potentiated in the hippocampus of drug-resistant epileptic rats induced by amygdala kindling. Neuroimmunomodulation 27(2):104–112. https://doi.org/10.1159/000510399
Barton ME, Klein BD, Wolf HH, White HS (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47(3):217–227
Mejía-Granados DM, Villasana-Salazar B, Lozano-García L, Cavalheiro EA, Striano P (2021) Gut-microbiota-directed strategies to treat epilepsy: clinical and experimental evidence. Seizure 90:80–92. https://doi.org/10.1016/j.seizure.2021.03.009
Rao M, Gershon MD (2016) The bowel and beyond: the enteric nervous system in neurological disorders. Nat Rev Gastroenterol Hepatol 13(9):517–528. https://doi.org/10.1038/nrgastro.2016.107
Fülling C, Dinan TG, Cryan JF (2019) Gut microbe to brain signaling: what happens in vagus. Neuron 101(6). https://doi.org/10.1016/j.neuron.2019.02.008
Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, Shen X, Bohórquez DV (2018) A gut-brain neural circuit for nutrient sensory transduction. Science 361(6408). https://doi.org/10.1126/science.aat5236
Muller PA, Schneeberger M, Matheis F, Wang P, Kerner Z, Ilanges A, Pellegrino K et al (2020) Microbiota modulate sympathetic neurons via a gut-brain circuit. Nature 583(7816):441–446. https://doi.org/10.1038/s41586-020-2474-7
van Vliet EA, Aronica E, Gorter JA (2015) Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol 38:26–34. https://doi.org/10.1016/j.semcdb.2014.10.003
Dhaher R, Gruenbaum SE, Sandhu MRS, Ottestad-Hansen S, Tu N, Wang Y, Lee T-SW, Deshpande K et al (2021) Network-related changes in neurotransmitters and seizure propagation during rodent epileptogenesis. Neurology 96(18):e2261–e2271. https://doi.org/10.1212/WNL.0000000000011846
Maciejak P, Szyndler J, Turzyńska D, Sobolewska A, Kołosowska K, Krząścik P, Płaźnik A (2016) Is the interaction between fatty acids and tryptophan responsible for the efficacy of a ketogenic diet in epilepsy? The new hypothesis of action. Neuroscience 313:130–148. https://doi.org/10.1016/j.neuroscience.2015.11.029
Gao K, Mu CL, Farzi A, Zhu WY (2020) Tryptophan metabolism: a link between the gut microbiota and brain. Adv Nutr (Bethesda, Md) 11(3):709–723. https://doi.org/10.1093/advances/nmz127
Fung TC (2020) The microbiota-immune axis as a central mediator of gut-brain communication. Neurobiol Dis 136:104714. https://doi.org/10.1016/j.nbd.2019.104714
Sochocka M, Donskow-Łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J (2019) The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer’s disease-a critical review. Mol Neurobiol 56(3):1841–1851. https://doi.org/10.1007/s12035-018-1188-4
Matson V, Chervin CS, Gajewski TF (2021) Cancer and the microbiome-influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology 160(2):600–613. https://doi.org/10.1053/j.gastro.2020.11.041
Zhou L, Chu C, Teng F, Bessman NJ, Goc J, Santosa EK, Putzel GG, Kabata H et al (2019) Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature 568(7752):405–409. https://doi.org/10.1038/s41586-019-1082-x
Leite AZ, Rodrigues NC, Gonzaga MI, Paiolo JCC, de Souza CA, Stefanutto NAV, Omori WP, Pinheiro DG et al (2017) Detection of increased plasma interleukin-6 levels and prevalence of and in the feces of type 2 diabetes patients. Front Immunol 8:1107. https://doi.org/10.3389/fimmu.2017.01107
Xu Y, Wang Y, Li H, Dai Y, Chen D, Wang M, Jiang X, Huang Z et al (2021) Altered fecal microbiota composition in older adults with frailty. Front Cell Infect Microbiol 11:696186. https://doi.org/10.3389/fcimb.2021.696186
Wang N, Liu H, Ma B, Zhao T, Chen Y, Yang Y, Zhao P, Han X (2021) CSF high-mobility group box 1 is associated with drug-resistance and symptomatic etiology in adult patients with epilepsy. Epilepsy Res 177:106767. https://doi.org/10.1016/j.eplepsyres.2021.106767
Walker LE, Sills GJ, Jorgensen A, Alapirtti T, Peltola J, Brodie MJ, Marson AG, Vezzani A et al (2021) High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: a proof-of-concept study. Epilepsia. https://doi.org/10.1111/epi.17116
Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T et al (2013) Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500(7461):232–236. https://doi.org/10.1038/nature12331
Weidner LD, Kannan P, Mitsios N, Kang SJ, Hall MD, Theodore WH, Innis RB, Mulder J (2018) The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue. Epilepsia 59(8):1507–1517. https://doi.org/10.1111/epi.14505
Xu D, Robinson AP, Ishii T, Duncan DAS, Alden TD, Goings GE, Ifergan I, Podojil JR et al (2018) Peripherally derived T regulatory and γδ T cells have opposing roles in the pathogenesis of intractable pediatric epilepsy. J Exp Med 215(4):1169–1186. https://doi.org/10.1084/jem.20171285
de Vries EE, van den Munckhof B, Braun KPJ, van Royen-Kerkhof A, de Jager W, Jansen FE (2016) Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neurosci Biobehav Rev 63:177–190. https://doi.org/10.1016/j.neubiorev.2016.02.007
Roseti C, van Vliet EA, Cifelli P, Ruffolo G, Baayen JC, Di Castro MA, Bertollini C, Limatola C et al (2015) GABAA currents are decreased by IL-1β in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis. Neurobiol Dis 82:311–320. https://doi.org/10.1016/j.nbd.2015.07.003
Lum GR, Olson CA, Hsiao EY (2020) Emerging roles for the intestinal microbiome in epilepsy. Neurobiol Dis 135:104576. https://doi.org/10.1016/j.nbd.2019.104576
Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019) The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol 16(8):461–478. https://doi.org/10.1038/s41575-019-0157-3
Cleophas MCP, Ratter JM, Bekkering S, Quintin J, Schraa K, Stroes ES, Netea MG, Joosten LAB (2019) Effects of oral butyrate supplementation on inflammatory potential of circulating peripheral blood mononuclear cells in healthy and obese males. Sci Rep 9(1):775. https://doi.org/10.1038/s41598-018-37246-7
Kennedy PJ, Cryan JF, Dinan TG, Clarke G (2017) Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology 112(Pt B):399–412. https://doi.org/10.1016/j.neuropharm.2016.07.002
Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, Buchhalter JR, Caraballo RH et al (2018) Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the international ketogenic diet study group. Epilepsia Open 3(2):175–192. https://doi.org/10.1002/epi4.12225
Sondhi V, Agarwala A, Pandey RM, Chakrabarty B, Jauhari P, Lodha R, Toteja GS, Sharma S et al (2020) Efficacy of ketogenic diet, modified atkins diet, and low glycemic index therapy diet among children with drug-resistant epilepsy: a randomized clinical trial. JAMA Pediatr 174(10):944–951. https://doi.org/10.1001/jamapediatrics.2020.2282
Wu HC, Dachet F, Ghoddoussi F, Bagla S, Fuerst D, Stanley JA, Galloway MP, Loeb JA (2017) Altered metabolomic-genomic signature: a potential noninvasive biomarker of epilepsy. Epilepsia 58(9):1626–1636. https://doi.org/10.1111/epi.13848
Murgia F, Muroni A, Puligheddu M, Polizzi L, Barberini L, Orofino G, Solla P, Poddighe S et al (2017) Metabolomics as a tool for the characterization of drug-resistant epilepsy. Front Neurol 8:459. https://doi.org/10.3389/fneur.2017.00459
Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, Uneyama H, Edwards RH et al (2010) Metabolic control of vesicular glutamate transport and release. Neuron 68(1). https://doi.org/10.1016/j.neuron.2010.09.002
Dahlin M, Elfving A, Ungerstedt U, Amark P (2005) The ketogenic diet influences the levels of excitatory and inhibitory amino acids in the CSF in children with refractory epilepsy. Epilepsy Res 64(3):115–125
Freeman J, Veggiotti P, Lanzi G, Tagliabue A, Perucca E (2006) The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res 68(2):145–180
Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, Turnbaugh JA, Verdin E et al (2020) Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells. Cell 181(6). https://doi.org/10.1016/j.cell.2020.04.027
Hartman AL, Zheng X, Bergbower E, Kennedy M, Hardwick JM (2010) Seizure tests distinguish intermittent fasting from the ketogenic diet. Epilepsia 51(8):1395–1402. https://doi.org/10.1111/j.1528-1167.2010.02577.x
Wei S, Mortensen MS, Stokholm J, Brejnrod AD, Thorsen J, Rasmussen MA, Trivedi U, Bisgaard H et al (2018) Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: a double-blind, randomized, placebo-controlled trial. EBioMedicine 38:265–272. https://doi.org/10.1016/j.ebiom.2018.11.035
Schmidt EKA, Raposo PJF, Torres-Espin A, Fenrich KK, Fouad K (2021) Beyond the lesion site: minocycline augments inflammation and anxiety-like behavior following SCI in rats through action on the gut microbiota. J Neuroinflammation 18(1):144. https://doi.org/10.1186/s12974-021-02123-0
Sutter R, Rüegg S, Tschudin-Sutter S (2015) Seizures as adverse events of antibiotic drugs: a systematic review. Neurology 85(15):1332–1341. https://doi.org/10.1212/WNL.0000000000002023
Wanleenuwat P, Suntharampillai N, Iwanowski P (2020) Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations. Seizure 81:167–174. https://doi.org/10.1016/j.seizure.2020.08.012
Amlerova J, Šroubek J, Angelucci F, Hort J (2021) Evidences for a role of gut microbiota in pathogenesis and management of epilepsy. Int J Mol Sci 22(11). https://doi.org/10.3390/ijms22115576
Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I (2017) Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother 72(10):2891–2897. https://doi.org/10.1093/jac/dkx209
Mazarati A, Medel-Matus J-S, Shin D, Jacobs JP, Sankar R (2021) Disruption of intestinal barrier and endotoxemia after traumatic brain injury: implications for post-traumatic epilepsy. Epilepsia 62(6):1472–1481. https://doi.org/10.1111/epi.16909
Medel-Matus J-S, Lagishetty V, Santana-Gomez C, Shin D, Mowrey W, Staba RJ, Galanopoulou AS, Sankar R et al (2022) Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia 63(7):1835–1848. https://doi.org/10.1111/epi.17248
Dong L, Zheng Q, Cheng Y, Zhou M, Wang M, Xu J, Xu Z, Wu G et al (2022) Gut microbial characteristics of adult patients with epilepsy. Front Neurosci 16:803538. https://doi.org/10.3389/fnins.2022.803538
Russo E (2022) The gut microbiota as a biomarker in epilepsy. Neurobiol Dis 163:105598. https://doi.org/10.1016/j.nbd.2021.105598
Lee K, Kim N, Shim JO, Kim G-H (2020) Gut bacterial dysbiosis in children with intractable epilepsy. J Clin Med 10(1). https://doi.org/10.3390/jcm10010005
Xu L, Chen D, Zhao C, Jiang L, Mao S, Song C, Gao F (2021) Decreased abundance of Akkermansia after adrenocorticotropic hormone therapy in patients with West syndrome. BMC Microbiol 21(1):126. https://doi.org/10.1186/s12866-021-02189-z
Wan L, Yang G, Zhang S, Sun Y, Li Z, Wang J, Shi X, Zou L (2021) Investigation of the association between imbalance of the intestinal flora and infantile spasms: a pilot case-control study. Transl Pediatr 10(4):819–833. https://doi.org/10.21037/tp-20-384
Gong X, Liu Y, Liu X, Li AQ, Guo KD, Zhou D, Hong Z (2022) Analysis of gut microbiota in patients with epilepsy treated with valproate: results from a three months observational prospective cohort study. Microb Pathog 162:105340. https://doi.org/10.1016/j.micpath.2021.105340
Eekers DBP, Pijnappel EN, Schijns OEMG, Colon A, Hoeben A, Zindler JD, Postma AA, Hoffmann AL et al (2018) Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: a systematic review. Seizure 55:83–92. https://doi.org/10.1016/j.seizure.2018.01.009
Gross RE, Stern MA, Willie JT, Fasano RE, Saindane AM, Soares BP, Pedersen NP, Drane DL (2018) Stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Ann Neurol 83(3):575–587. https://doi.org/10.1002/ana.25180
Krishna V, Sammartino F, Rezai A (2018) A review of the current therapies, challenges, and future directions of transcranial focused ultrasound technology: advances in diagnosis and treatment. JAMA Neurol 75(2):246–254. https://doi.org/10.1001/jamaneurol.2017.3129
Mengoni F, Salari V, Kosenkova I, Tsenov G, Donadelli M, Malerba G, Bertini G, Del Gallo F et al (2021) Gut microbiota modulates seizure susceptibility. Epilepsia 62(9):e153–e157. https://doi.org/10.1111/epi.17009
Funding
This work was supported by Liaoning Directed project for the planning of science and technology No.2021JH2/10300135 (to J.L.); Liaoning Province Excellent Talent Program Project No.xlyc1902031 (to J.L.); Dalian High-level Talent Team Project No.2022RG18 (to J.L.); National Health and Family Planning Commission and Food and Drug Administration No.CMR-20161129-1003 (to J.L.); Dalian Medical Science Research Project, No.2112006 (to Y.J.); and Dalian high-level talent innovation support plan, No. 2021RQ028 (to C.H.).
Author information
Authors and Affiliations
Contributions
All authors contributed to the manuscript. Conceptualization: Jing Liu and Wei Zou; writing—original draft preparation: Shuna Chen and Yang Jiao; writing—review and editing: Shuna Chen and Yang Jiao; visualization: Chao Han and Ying Li; supervision: Jing Liu and Wei Zou. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics Approval
Not applicable.
Informed Consent
Not applicable.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, S., Jiao, Y., Han, C. et al. Drug-Resistant Epilepsy and Gut-Brain Axis: an Overview of a New Strategy for Treatment. Mol Neurobiol (2023). https://doi.org/10.1007/s12035-023-03757-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12035-023-03757-2